123 related articles for article (PubMed ID: 23813855)
21. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
[TBL] [Abstract][Full Text] [Related]
22. Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Tintori C; La Sala G; Vignaroli G; Botta L; Fallacara AL; Falchi F; Radi M; Zamperini C; Dreassi E; Dello Iacono L; Orioli D; Biamonti G; Garbelli M; Lossani A; Gasparrini F; Tuccinardi T; Laurenzana I; Angelucci A; Maga G; Schenone S; Brullo C; Musumeci F; Desogus A; Crespan E; Botta M
J Med Chem; 2015 Jun; 58(11):4590-609. PubMed ID: 25923950
[TBL] [Abstract][Full Text] [Related]
23. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
24. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
25. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
Saito Y; Yuki H; Kuratani M; Hashizume Y; Takagi S; Honma T; Tanaka A; Shirouzu M; Mikuni J; Handa N; Ogahara I; Sone A; Najima Y; Tomabechi Y; Wakiyama M; Uchida N; Tomizawa-Murasawa M; Kaneko A; Tanaka S; Suzuki N; Kajita H; Aoki Y; Ohara O; Shultz LD; Fukami T; Goto T; Taniguchi S; Yokoyama S; Ishikawa F
Sci Transl Med; 2013 Apr; 5(181):181ra52. PubMed ID: 23596204
[TBL] [Abstract][Full Text] [Related]
26. An update on dual Src/Abl inhibitors.
Musumeci F; Schenone S; Brullo C; Botta M
Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
[TBL] [Abstract][Full Text] [Related]
28. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
[TBL] [Abstract][Full Text] [Related]
29. Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase.
Choi HJ; Smithgall TE
J Mol Biol; 2004 Nov; 343(5):1255-68. PubMed ID: 15491611
[TBL] [Abstract][Full Text] [Related]
30. Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative.
Chakraborty MP; Bhattacharyya S; Roy S; Bhattacharya I; Das R; Mukherjee A
J Biol Chem; 2021; 296():100449. PubMed ID: 33617879
[TBL] [Abstract][Full Text] [Related]
31. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
[TBL] [Abstract][Full Text] [Related]
32. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
33. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism.
Dutartre H; Harris M; Olive D; Collette Y
Virology; 1998 Aug; 247(2):200-11. PubMed ID: 9705913
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
[TBL] [Abstract][Full Text] [Related]
35. Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity.
Emert-Sedlak LA; Narute P; Shu ST; Poe JA; Shi H; Yanamala N; Alvarado JJ; Lazo JS; Yeh JI; Johnston PA; Smithgall TE
Chem Biol; 2013 Jan; 20(1):82-91. PubMed ID: 23352142
[TBL] [Abstract][Full Text] [Related]
36. Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds.
Emert-Sedlak L; Kodama T; Lerner EC; Dai W; Foster C; Day BW; Lazo JS; Smithgall TE
ACS Chem Biol; 2009 Nov; 4(11):939-47. PubMed ID: 19807124
[TBL] [Abstract][Full Text] [Related]
37. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
38. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
39. Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms.
Hassan R; Suzu S; Hiyoshi M; Takahashi-Makise N; Ueno T; Agatsuma T; Akari H; Komano J; Takebe Y; Motoyoshi K; Okada S
J Cell Physiol; 2009 Nov; 221(2):458-68. PubMed ID: 19585521
[TBL] [Abstract][Full Text] [Related]
40. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
Moarefi I; LaFevre-Bernt M; Sicheri F; Huse M; Lee CH; Kuriyan J; Miller WT
Nature; 1997 Feb; 385(6617):650-3. PubMed ID: 9024665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
